MAPT and Alzheimer disease: In PS19 mice, tau pathology typically results in decreased survival due to severe paralysis, however PU-AD administration from 3 months of age until death was well tolerated and significantly increased survival, with 50% of treated male mice having a 100–150-day delay in the terminal paralysis phenotype (P = 0.0022).